Patents by Inventor Mathew Alexander Vadas

Mathew Alexander Vadas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA sequences for human angiogenesis genes
    Publication number: 20080292614
    Abstract: Novel nucleic acid sequences and encoded polypeptides involved in the process of angiogenesis are provided. In particular, provided are a BNO69 nucleic acid of SEQ ID NO: 1 and a BNO69 polypeptide of SEQ ID NO: 115. Methods are provided for treating subjects having pathologies associated with angiogenesis and for the screening of drugs for pro- or anti-angiogenic activity.
    Type: Application
    Filed: January 17, 2008
    Publication date: November 27, 2008
    Inventors: Jennifer Ruth Gamble, Christopher Norman Hahn, Mathew Alexander Vadas
  • Method of Treating Cellular Damage
    Publication number: 20080279897
    Abstract: The present invention relates generally to a method of modulating hyperglycaemia-induced endothelial cell functioning and agents useful for same. More particularly, the present invention relates to a method of modulating hyperglycaemia-induced vascular endothelial cell functioning by modulating intracellular sphingosine kinase-mediated signalling. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of the adverse vascular endothelial cell functioning associated with conditions characterised by hyperglycaemia, and/or diabetes mellitus, per se.
    Type: Application
    Filed: January 17, 2006
    Publication date: November 13, 2008
    Applicant: MEDVET SCIENCE PTY. LTD.
    Inventors: Pu Xia, Lijun Wang, Mathew Alexander Vadas
  • Haemopoietic growth factor antagonists and uses therefor
    Patent number: 6322791
    Abstract: The present invention relates generally to variant recombinant forms of haemopoietic growth factors useful as antagonists to the corresponding native haemopoietic growth factor and their use in ameliorating aberrant effects caused by the native molecules and in the treatment of tumours and cancers and inflammation.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: November 27, 2001
    Assignee: BreasaGen Limited
    Inventors: Mathew Alexander Vadas, Angel Francisco Lopez, Mary Francis Shannon, Keat-Chye Cheah, Carol Ruth Senn, Stan Bastiras, Allan Robins
  • Modified forms of granulocyte macrophage-colony stimulating factor as antagonists
    Patent number: 5939063
    Abstract: The present invention relates to modified and variant forms of haemopoietic growth factors (HGF) capable of acting as antagonists to the corresponding native haemopoietic growth factors and their use in ameliorating aberrant effects caused by the native molecules. A modified haemopoietic growth factor (HGF) is characterized by being in unglycosylated form and comprising a sequence of amino acids within a first .alpha.-helix wherein one or more exposed amino acids in said first .alpha.-helix having acidic or acidic-like properties are substituted with a basic amino acid residue. The preferred HGF are granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, G-CSF and erythropoietin (EPO).
    Type: Grant
    Filed: April 8, 1996
    Date of Patent: August 17, 1999
    Assignee: Medvet Science Pty. Ltd.
    Inventors: Mathew Alexander Vadas, Angel Francisco Lopez, Mary Frances Shannon